2023 年第 8 期 第 18 卷

养血清脑颗粒联合奥拉西坦治疗阿尔茨海默病临床研究

Clinical study on treatment of Alzheimer′s disease with Yangxue Qingnao granule and oxiracetam

作者：李佩珊1陈宝1吉彩云1林明龙2吴淑燕3

英文作者：Li Peishan1 Chen Bao1 Ji Caiyun1 Lin Minglong2 Wu Shuyan3

单位：1中南大学湘雅医学院附属海口医院药学部，海口570208；2海南省中医院药学部，海口570203；3广东省人民医院南海医院药剂科，佛山528251

英文单位：1Department of Pharmacy Haikou Affiliated Hospital of Central South University Xiangya School of Medicine Haikou 570208 China; 2Department of Pharmacy Hainan Traditional Chinese Medicine Hospital Haikou 570203 China; 3Department of Pharmacy Nanhai Hospital of Guangdong Provincial People′s Hospital Foshan 528251 China

关键词：阿尔茨海默病；养血清脑颗粒；奥拉西坦

英文关键词：Alzheimer′sdisease;YangxueQingnaogranule;Oxiracetam

• 摘要：

• 目的 观察养血清脑颗粒联合奥拉西坦治疗阿尔茨海默病的临床效果。方法 选取中南大学湘雅医学院附属海口医院2020年3月至2022年2月收治的阿尔茨海默病患者124例。按照随机数字表法分为对照组（奥拉西坦治疗，62例）和观察组（养血清脑颗粒联合奥拉西坦治疗，62例）。2组均持续治疗6个月。比较2组疗效，治疗前后痴呆病理行为评定表（BEHAVE-AD）、日常生活能力量表（ADL）、蒙特利尔认知评估量表（MoCA）评分、血清指标［高敏C反应蛋白（hs-CRP）、白细胞介素1β（IL-1β）、β淀粉样蛋白1-42（Aβ1-42）、Tau蛋白］水平和不良反应发生情况。结果 观察组的临床总有效率高于对照组［91.9%（57/62）比77.4%（48/62）］，差异有统计学意义（χ2=5.035，P=0.025）。2组治疗6个月后BEHAVE-AD、ADL评分低于治疗前，MoCA评分高于治疗前，且观察组BEHAVE-AD、ADL评分低于对照组，MoCA评分高于对照组，差异均有统计学意义（均P＜0.05）。2组治疗6个月后hs-CRP、IL-1β、Aβ1-42、Tau蛋白水平均低于治疗前，且观察组均低于对照组，差异均有统计学意义（均P＜0.05）。观察组与对照组不良反应总发生率比较［12.9%(8/62)比11.3%(7/62)］差异无统计学意义（χ2=0.076,P=0.783）。结论 养血清脑颗粒联合奥拉西坦可有效改善阿尔茨海默病患者的临床症状，提高患者的认知功能和日常生活能力，调节血清hs-CRP、IL-1β、Aβ1-42、Tau蛋白水平。

• Objective To observe the clinical effect of Yangxue Qingnao granule combined with oxiracetam on the treatment of Alzheimer′s disease. Methods  From March 2020 to February 2022, 124 patients with Alzheimer′s disease admitted to Haikou Affiliated Hospital of Central South University Xiangya School of Medicine were selected. They were divided into the control group (treated with oxiracetam, 62 cases) and the observation group (treated with Yangxue Qingnao granule combined with oxiracetam, 62 cases) according to the random number table method. Both groups were continuously treated for 6 months. The curative effect, the scores of Behavioral Pathology in Alzheimer′s Disease Rating Scale (BEHAVE-AD), activity of daily living scale(ADL), Montreal Cognitive Assessment(MoCA), levels of serum indexes ［high-sensitivity C-reactive protein (hs-CRP), interleukin-1β（IL-1β）, β amyloid 1-42 (Aβ1-42), Tau protein］ before and after treatment, and occurrence of adverse reactions between the two groups were compared. Results The clinical total effective rate in the observation group was higher than that in the control group ［91.9%(57/62) vs 77.4%(48/62)］(χ2=5.035, P=0.025). After 6 months of treatment, the scores of BEHAVE-AD and ADL in the two groups were lower than those before treatment, the scores of MoCA were higher than those before treatment, the scores of BEHAVE-AD and ADL in the observation group were lower than those in the control group, and the scores of MoCA were higher than those in the control group (all P＜0.05). The levels of hs-CRP, IL-1β, Aβ1-42 and Tau protein in the two groups after 6 months of treatment were lower than those before treatment, and those in the observation group were lower than those in the control group(all P＜0.05). There was no statistically significant difference in the total incidence of adverse reactions between the observation group and the control group ［12.9%(8/62) vs 11.3%(7/62)］(χ2=0.076, P=0.783). Conclusion Yangxue Qingnao granule combined with oxiracetam can effectively improve the clinical symptoms of patients with Alzheimer′s disease, improve the cognitive function and daily living ability of patients, and regulate the levels of serum hs-CRP, IL-1β, Aβ1-42, Tau protein.